Accra has turned down a health agreement with Washington over access to medical records, pathogen information and alleged restrictions on drug oversight — a decision that has reignited the debate on Africa’s health sovereignty.

ACCRA — Ghana has just posed a question that reaches far beyond the borders of its health system: what is a nation’s sovereignty worth when foreign financial aid comes with sensitive strings attached?

Accra’s answer is now clear: not $109 million.

The Ghanaian government has rejected a new health agreement proposed by the United States, which would have brought in roughly $109 million in American funding over five years. The overall package was valued at approximately $300 million, taking into account expected complementary contributions from Ghana.

President John Dramani Mahama confirmed and explained the rejection during an address at the Council on Foreign Relations in New York on 25 September.

And his words struck a chord.

“Who takes another country’s medical records?”

According to the Ghanaian president, the draft agreement included provisions for transmitting Ghana’s pathogen profiles and medical data to the United States. He also stated that the text imposed a counterpart funding obligation on Ghana and contained clauses concerning control over medical products entering the country.

For Mahama, these conditions were simply “humiliating.”

What Washington was actually asking for

The matter deserves a closer look beyond the headline-grabbing phrase.

Ghana did not reject a $100 million package simply because it came from the United States. The issue lies with the conditions attached to the funding.

The Associated Press reported in May that the draft agreement, worth around $300 million overall, would have provided Ghana with about $109 million over five years. Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, indicated that certain provisions would have allowed access to sensitive health data in circumstances potentially enabling the identification of individuals. According to him, the scope of that access went far beyond what is normally necessary.

The BMJ also reported that the Ghanaian draft included access to health data and pathogens for 16 American companies. The journal noted, however, that several clauses in the new US health agreements remain difficult to scrutinise publicly, as not all negotiated texts have been made public.

A nuance is therefore needed here: it would be excessive to claim that the United States was demanding unrestricted access to “all Ghanaians’ medical data.” What is documented, however, are Ghanaian concerns about the extent of access to health data and pathogen information.

Why this data matters so much

Behind medical records lies a genuine question of power.

Health data reveals which diseases are circulating, where they are spreading, which populations are most exposed and how epidemics are evolving.

Pathogen data can also hold considerable scientific value. It can contribute to research on vaccines, treatments and surveillance of new outbreaks.

This is precisely what is fuelling concerns among several African governments.

In February 2026, Jean Kaseya, director-general of the Africa Centres for Disease Control and Prevention (Africa CDC), had already expressed serious concerns about data and pathogen-sharing provisions in the new US health agreements. Reuters reported at the time that some agreements required rapid sharing of sensitive data without guaranteeing African countries access to treatments or vaccines that might result from that information.

Ghana is therefore not an isolated case.

Accra no longer wants to depend entirely on foreign aid

The rejection also comes in a particular context.

Since the suspension of a large portion of US aid programmes, Ghana has been seeking to reduce its reliance on external funding. In February 2025, the Ghanaian presidency had already estimated the shortfall caused by the suspension of USAID funding at $156 million, of which $78.2 million directly concerned essential health programmes.

The Mahama government is now pushing the idea of “health sovereignty.”

This direction was reinforced in September with the launch of the report A Sovereign Future for Health, presented as part of the Accra Reset initiative. The document proposes, among other things, reducing Southern countries’ dependence on external funding and strengthening their own health systems.

Accra’s message is therefore relatively clear: Ghana wants to continue working with its foreign partners, but on the basis of agreements it considers more balanced.

Another sticking point: medicines

The other element revealed by Mahama is particularly sensitive.

According to the president, the draft agreement provided that certain medicines and medical products supplied under the programme would not be subject to controls by Ghana’s Food and Drugs Authority (FDA).

This claim has not been publicly confirmed in detail by the US government, which, when questioned by the Associated Press, said it does not comment on the details of bilateral negotiations.

But if this provision does indeed match the text presented to the Ghanaian government, it explains part of Accra’s firmness: for the authorities, health funding should not lead to reducing the national regulator’s ability to control medical products used on its territory.

And the American response?

Washington has not publicly detailed the contested clauses.

A US State Department spokesperson said the United States does not disclose the details of bilateral negotiations, while maintaining that Washington is still looking for ways to strengthen its partnership with Ghana.

This lack of full publication of the text makes it impossible to settle certain essential questions.

Exactly what data would have been accessible?

To which American companies or institutions?

Under what circumstances could individuals have been identified?

How long would the data have been retained?

What legal guarantees would have protected Ghanaian patients?

On these points, public information remains incomplete.

Ghana opens a debate that goes beyond Ghana

The real issue in this affair may lie there.

For decades, many African health systems have depended on funding, medicines, equipment and programmes from abroad. These partnerships have saved lives and helped fight major diseases.

But the digital transformation of health is now changing the nature of cooperation.

Aid is no longer just about money, medicines or equipment. It can also provide access to a strategic resource: data.

And Ghana has just reminded everyone that it intends to retain control of that resource.

John Mahama says his government rejected the draft after its review by the Ministry of Health and its passage through Cabinet. He also says the decision had the support of the entire government and that the rejection was decided very quickly.

Ghana will now have to demonstrate that it can fill the abandoned funding gap without compromising its health programmes.

But for Accra, the choice seems deliberate:

better to look for other partners than to sign an agreement the government considers incompatible with health sovereignty and the protection of Ghanaians’ data.

The question Ghana is now putting to its foreign partners is simple:

When Africa receives aid to care for its people, must it also surrender control over information about those people?

The debate is probably only just beginning.

By Boureima Amadou — Reporter